XML 66 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating Income (Loss) [Abstract]    
Net sales $ 2,843 $ 2,899
Cost of sales (1,808) (1,875)
Research and development expenses (164) (166)
Selling and administrative expenses (461) (490)
Depreciation & Amortization (236) (278)
Interest Expense (71) (83)
Other expense, net (20) (1)
Restructuring and other charges (17) (3)
Impairment (1,153) 0
Divestiture and integration costs (51)  
Business Combination, Divestitures And Integration Costs   (58)
Strategic initiative costs (8) (4)
Regulatory costs (11) (35)
Other costs (5) (1)
(Loss) income before taxes (994) 115
Business divestiture costs 51 56
Integration-related costs   2
Taste    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (2) (1)
Impairment 0  
Food Ingredients    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (3) (1)
Impairment (1,153)  
Health & Biosciences    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (3) (1)
Scent    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (9) 0
Impairment 0  
Pharma Solutions    
Operating Income (Loss) [Abstract]    
Impairment 0  
Operating Segments    
Operating Income (Loss) [Abstract]    
Net sales 2,843 2,899
Adjusted Operating EBITDA 578 578
Operating Segments | Taste    
Operating Income (Loss) [Abstract]    
Net sales 627 619
Cost of sales (377) (384)
Research and development expenses (40) (39)
Selling and administrative expenses (94) (96)
Depreciation expense add-back 15 17
Adjusted Operating EBITDA 131 117
Operating Segments | Food Ingredients    
Operating Income (Loss) [Abstract]    
Net sales 796 856
Cost of sales (609) (673)
Research and development expenses (12) (20)
Selling and administrative expenses (92) (90)
Depreciation expense add-back (28) (35)
Adjusted Operating EBITDA 111 108
Operating Segments | Health & Biosciences    
Operating Income (Loss) [Abstract]    
Net sales 540 529
Cost of sales (298) (286)
Research and development expenses (52) (46)
Selling and administrative expenses (81) (88)
Depreciation expense add-back 29 29
Adjusted Operating EBITDA 138 138
Operating Segments | Scent    
Operating Income (Loss) [Abstract]    
Net sales 614 645
Cost of sales (344) (350)
Research and development expenses (55) (55)
Selling and administrative expenses (86) (88)
Depreciation expense add-back (15) (16)
Adjusted Operating EBITDA 144 168
Operating Segments | Pharma Solutions    
Operating Income (Loss) [Abstract]    
Net sales 266 250
Cost of sales (180) (181)
Research and development expenses (5) (6)
Selling and administrative expenses (32) (28)
Depreciation expense add-back (5) (12)
Adjusted Operating EBITDA $ 54 $ 47